Publication | Closed Access

Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors

OncologyOncogenic AgentMedicineBraf InhibitorPharmacotherapyAnti-cancer AgentCancer TreatmentParticle SizePharmacologyRadiation OncologyCancer ResearchBraf Mutation-positive Tumors